Sitagliptin in Combination With Metformin and Sulfonylurea

Phase 4 Completed 108 enrolled Charles Drew University of Medicine and Science National Center for Research Resources (NCRR) · collab

NaSingle-groupOpen-labelTreatment

Summary

This study will compare the effect of a new oral agent for type 2 diabetes, sitagliptin, in comparison to thiazolidinediones as the third-line oral agent, in patients with type 2 diabetes mellitus.

Timeline

Start: 2008-01
Primary completion: 2010-03
Completion: 2010-03

Publications

Hsia SH, Navar MD, Duran P, Shaheen M, Davidson MB. Sitagliptin compared with thiazolidinediones as a third-line oral antihyperglycemic agent in type 2 diabetes mellitus. Endocr Pract. 2011 Sep-Oct;17(5):691-8. doi: 10.4158/EP10405.OR.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sitagliptin	Small molecule	100 mg	Oral

Sitagliptin in Combination With Metformin and Sulfonylurea

Summary

Timeline

Publications

Drugs

Indications